Global Large-Scale Real-World Assessment Of Drug-Associated Galactorrhea Based On FDA Adverse Drug Reaction Reports

This study provides a comprehensive list of high-risk drugs for DAG, offering critical data to guide safer prescribing and improve pharmacovigilance. Clinicians should be vigilant in monitoring for suggestive symptoms like galactorrhea, amenorrhea and sexual dysfunction, especially in high-risk individuals on long-term treatment with prolactin-elevating medications. These findings underscore the importance of patient safety and inform clinical practice.